^
Association details:
| Biomarker: | IDH2 mutation + TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4274 Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia
Published date:
11/02/2023
Excerpt:
Patients received AZA 100mg on D1-7, VEN 200mg on D1-14, and CHI 30mg biweekly...Pretreatment IDH1 and IDH2 mutations were associated with higher CRc rates (75% and 50%, respectively). The CRc rate in patients with TP53 mutations was 67%, with response noted among patients with concurrent IDH1/IDH2 mutations...The combination of VEN and CHI plus AZA (VCA) demonstrated manageable safety and encouraging efficacy in patients with R/R AML. IDH1/IDH2 mutations were associated with the sensitivity of VCA, even in some patients with concurrent TP53 mutations.
Secondary therapy:
azacitidine
